Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q1 FY2025-26 Earnings Presentation
16 slides from Gujarat Themis Biosyn's earnings presentation, Aug 1, 2025
Slide 1: Gujarat Themis Biosyn Limited
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2025-26/17 1st August, 2025 The Manager The Manager – Listing Department Corporate
Slide 2: Investor Presentation Q1 FY2025-26
Gujarat Themis Biosyn Limited Investor Presentation Q1 FY2025-26
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Management Comment
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said: “This quarter’s performance has been in line with expectations. We continue to demonstrate resilience in navigating fluctuations and remain on-course with our expansion endeavors. An unusual
Slide 5: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 38.8 39.5 37.7 35.9 34.7 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 60% 47.8% 47.7% 14 34.1% 40% 44.3% 42.5% 50% 32.8% 20 31.8% 38.8% 12 30.4% 35% 40%
Slide 6: Q1 FY25-26 Financial Highlights
Click to Q1edit Master FY25-26 title style Financial Highlights Rs. Cr. Q1 FY25-26 Q1 FY24-25 YoY% Q4 FY24-25 Income from Operations 35.87 38.83 37.74 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 35.87 38.83 (7.62%) 37.74 Cost of Materials Consumed 6.83 6.16 6.85 Changes In Inv
Slide 7: FY24-25 Financial Highlights
Click to edit Master FY24-25 title Financial style Highlights Rs. Crs FY24-25 FY23-24 YoY% Income from Operations 150.80 169.82 Other Operating Income 0.00 0.00 Total Income from Operations 150.80 169.82 (11.20%) Cost of Materials Consumed 25.78 25.67 Changes In Inventory (1.27) 11.01 Employee Cost
Slide 8: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 169.82 148.39 150.80 114.85 90.56 FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 90 50.5% 49.6% 51% 46.4% 80 50% 70 39.1% 45% 45.7% 38.0% 70 49% 34.8% 40% 60 33.3% 32.3% 60 48
Slide 9: Balance Sheet Highlights – As on 31st March 2025
Click to edit Master Balance title style– As on 31st March 2025 Sheet Highlights Rs. Cr. As on 31st As on 31st Rs. Cr. As on 31st Mar, As on 31st Mar Total Equity & Liabilities Mar, 2025 Mar 2024 Total Assets 2025 2024 Shareholders Funds 248.38 201.38 Non Current Assets 249.34 173.55 Share Capital 1
Slide 10: Key Balance Sheet Ratios
Keyedit Click to Balance Sheet Master Ratios title style RoCE(%)* RoA(%)** 35.6% 34.9% 57.9% 26.8% 52.1% 39.4% 16.2% 23.6% FY21-22 FY22-23 FY23-24 FY24-25 FY21-22 FY22-23 FY23-24 FY24-25 RoE(%)*** 42.2% 38.9% 29.4% 19.6% FY21-22 FY22-23 FY23-24 FY24-25 Company has been investing in Capex over last t
Slide 11: Among India's few fermentation based intermediate manufacturers
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility ▪ Incorporated in 1981 as joint ▪ Plant in Vapi (Gujarat) sector Company with GIIC
Slide 12: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin ▪ An intermediate for Rifamycin S ▪ An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 13: Expansion Strategy to Spur Growth
Click to edit Master Expansion titletostyle Strategy Spur Growth Capex Plan Research & Development Forward Integration Fermentation ❖ Ventured into API production as ❖ New Product Development part of forward integration ❖ Expanding fermentation capacity ❖ R&D Unit Commissioned, as per strategy ❖ Add
Slide 14: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 13
Slide 15: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style ▪ In process of identifying new products which have good domestic & export New Product Development & potential ▪ Company strategizing to move up the value chain through forward integration into Forward Integration API – recently began commercial operation
Slide 16: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan Mr. Rahul Trivedi Mr. Amit Sharma pradeep.chandan@themismedicare.com rahul.trivedi@adfactorspr.com amit.
Gujarat Themis Biosyn — Q1 FY2025-26 Earnings Presentation on 6ix